Dorothy A. Frank
Nessuna posizione attualmente
Profilo
Dorothy A.
Frank formerly worked at Xanodyne Pharmaceuticals, Inc., as Senior Vice President-Regulatory Affairs and Neos Therapeutics, Inc., as Vice President-Regulatory Affairs.
Ms. Frank received her graduate degree from South Dakota School of Mines & Technology.
Precedenti posizioni note di Dorothy A. Frank
Società | Posizione | Fine |
---|---|---|
NEOS THERAPEUTICS, INC. | Consigliere Generale | - |
Xanodyne Pharmaceuticals, Inc.
Xanodyne Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management and women's healthcare. It markets a portfolio of prescription pharmaceuticals and a line of prenatal vitamins. The firm's product candidates include XP12B, a tranexamic acid modified release oral tablet for the reduction of menstrual blood loss in women, who suffer from menorrhagia or excessive menstrual bleeding; and XP20B is a combination propoxyphene and acetaminophen modified release oral tablet for the treatment of mild to moderate pain. The company was founded by Gilbert R. Gonzales and Roger Dale Griggs in May 2001 and is headquartered in Newport, KY. | Consigliere Generale | - |
Formazione di Dorothy A. Frank
South Dakota School of Mines & Technology | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
Xanodyne Pharmaceuticals, Inc.
Xanodyne Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management and women's healthcare. It markets a portfolio of prescription pharmaceuticals and a line of prenatal vitamins. The firm's product candidates include XP12B, a tranexamic acid modified release oral tablet for the reduction of menstrual blood loss in women, who suffer from menorrhagia or excessive menstrual bleeding; and XP20B is a combination propoxyphene and acetaminophen modified release oral tablet for the treatment of mild to moderate pain. The company was founded by Gilbert R. Gonzales and Roger Dale Griggs in May 2001 and is headquartered in Newport, KY. | Health Technology |
Neos Therapeutics, Inc.
Neos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX. | Health Technology |
- Borsa valori
- Insiders
- Dorothy A. Frank